Skip to main content
Premium Trial:

Request an Annual Quote

Exosome Diagnostics, PCF Partner to Improve Prostate Cancer Dx Technologies

NEW YORK (GenomeWeb News) – Exosome Diagnostics and the Prostate Cancer Foundation today announced a multi-year collaboration to assess the capabilities of RNA biofluid diagnostics for the detection of prostate cancer and to accelerate clinical validation of Exosome's technology for the disease.

The partnership will evaluate new RNA biofluid diagnostics for the early detection, progression monitoring, and advanced disease risk stratification in prostate cancer, Exosome and PCF said.

The collaboration, which brings together clinicians, researchers, and industry personnel, will support near-term in vitro clinical validation of known prostate cancer biomarkers and "a robust biomarker discovery program" for the disease "from diagnosis through progression and treatment."

"We believe that exosome technology may represent an opportunity to improve patient outcomes through more specific diagnosis than is currently available with the standard PSA test," Howard Soule, chief science officer of PCF, said in a statement. "Exosome technology may also help address growing concerns about over-diagnosis and over-treatment."

The partners also announced that Soule is joining Exosome's scientific advisory board.

Last week, the US Preventive Services Task Force issued a draft recommendation that healthy men should not be given the PSA test because, in addition to not saving lives, the test often results in more tests and treatments that are unnecessary.

Exosome CEO James McCullough said in a statement that the partnership with PCF "assures that we have the right people at the table on the front side of the clinical translation process to accurately assess unmet medical opportunities, properly design validation studies, and deliver exosome technology benefits quickly to patients."

Terms of the deal were not disclosed.

The Scan

Guidelines for Ancient DNA Work

More than two dozen researchers have developed new ethical guidelines for conducting ancient DNA research, which they present in Nature.

And Cleared

A UK regulator has cleared former UK Prime Minister David Cameron in concerns he should have registered as a consultant-lobbyist for his work with Illumina, according to the Financial Times.

Suit Over Allegations

The Boston Globe reports that David Sabatini, who was placed on leave from MIT after allegations of sexual harassment, is suing his accuser, the Whitehead Institute, and the institute's director.

Nature Papers on Esophageal Cancer, Origin of Modern Horses, Exome Sequencing of UK Biobank Participants

In Nature this week: genetic and environmental influences of esophageal cancer, domestic horse origin traced to Western Eurasian steppes, and more.